MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer.
Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S, Murakami T, Zhang X, Sekhar SC, Kim S, Ryu S, Knarr M, Vasilev SA, DiFeo A, Drapkin R, Hoon DSB.
Bustos MA, et al. Among authors: kobayashi y.
Cell Biosci. 2023 Nov 6;13(1):200. doi: 10.1186/s13578-023-01151-y.
Cell Biosci. 2023.
PMID: 37932806
Free PMC article.